NASDAQ:AIKI AIkido Pharma (AIKI) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free AIKI Stock Alerts $2.71 -0.05 (-1.81%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$2.70▼$2.8350-Day Range$1.95▼$2.9352-Week Range$3.31▼$11.48Volume11,031 shsAverage Volume79,326 shsMarket Capitalization$14.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial Media Get AIkido Pharma alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About AIkido Pharma Stock (NASDAQ:AIKI)AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.Read More AIKI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIKI Stock News HeadlinesApril 24, 2024 | americanbankingnews.comAIkido Pharma (NASDAQ:AIKI) Share Price Crosses Above Two Hundred Day Moving Average of $2.25April 16, 2024 | americanbankingnews.comAIkido Pharma (NASDAQ:AIKI) Shares Pass Above 200 Day Moving Average of $2.23April 24, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.March 17, 2024 | seekingalpha.comSNOA Sonoma Pharmaceuticals, Inc.January 23, 2024 | wsj.comRoyalty Pharma PLCOctober 6, 2023 | msn.comKengan Ashura: 10 Strongest Fighters, RankedSeptember 6, 2023 | markets.businessinsider.comDominari Holdings Inc. Releases Shareholder UpdateApril 10, 2023 | markets.businessinsider.comKyle Wool Appears on Fox BusinessApril 24, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 3, 2023 | markets.businessinsider.comDominari Holdings Appoints George Way As CFOMarch 27, 2023 | markets.businessinsider.comDominari Financial Inc. Acquires Leading Broker Dealer and Registered Investment Advisor BusinessMarch 21, 2023 | benzinga.comDominari Financial Granted Approval to Acquire Broker DealerMarch 14, 2023 | finance.yahoo.comDominari Holdings Provides Business UpdateDecember 28, 2022 | finance.yahoo.comDominari Holdings Provides Update on Share Repurchase ProgramDecember 22, 2022 | finanznachrichten.deAIkido Pharma Inc.: AIkido Pharma Announces Successful Initial Public Offering of ASP IsotopesDecember 22, 2022 | finance.yahoo.comAIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)November 28, 2022 | finance.yahoo.comAIkido Pharma Announces Successful Initial Public Offering of ASP IsotopesOctober 6, 2022 | finance.yahoo.comAIkido Share Repurchase ContinuesOctober 5, 2022 | finance.yahoo.comAIkido Purchases More SharesOctober 4, 2022 | finance.yahoo.comShare Repurchase Program ContinuesOctober 3, 2022 | finance.yahoo.comAIkido Pharma Continues Share Repurchase ProgramSeptember 30, 2022 | finance.yahoo.comAIkido Pharma Provides Update on Share Repurchase ProgramSeptember 9, 2022 | prnewswire.comDominari Financial, Inc. Executes Definitive Agreement to Buy Broker-DealerAugust 10, 2022 | ca.investing.comPre-Open Movers: Nielsen Climbs 20%, AppLivin Makes Offer for UnityAugust 10, 2022 | marketwatch.comAIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKIAugust 10, 2022 | nasdaq.comAIkido Pharma Receives Offer From Shalom Auerbach - Quick FactsAugust 10, 2022 | finance.yahoo.comAIkido Pharma Confirms Receipt of Unsolicited OfferSee More Headlines Receive AIKI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:AIKI CUSIPN/A CIK12239 Webwww.spherix.com Phone(112) 745-1374Fax703-992-9348Employees4Year Founded1967Profitability EPS (Most Recent Fiscal Year)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.21% Return on Assets-16.94% Debt Debt-to-Equity RatioN/A Current Ratio29.54 Quick Ratio29.54 Sales & Book Value Annual Sales$10,000.00 Price / Sales1,486.44 Cash FlowN/A Price / Cash FlowN/A Book Value$19.27 per share Price / Book0.14Miscellaneous Outstanding Shares5,485,000Free Float5,013,000Market Cap$14.86 million OptionableNot Optionable Beta0.93 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Anthony C. Hayes Esq. (Age 54)CEO, Principal Financial Officer, Principal Accounting Officer & Director Comp: $960kMr. Darrell DotsonVP of Drug Devel. & Gen. CounselMr. Carlos AldaveroPres of Dominari FinancialKey CompetitorsXcel BrandsNASDAQ:XELBbioAffinity TechnologiesNASDAQ:BIAFData Knights AcquisitionNASDAQ:DKDCANeuroBo PharmaceuticalsNASDAQ:NRBOETAO InternationalNASDAQ:ETAOView All Competitors AIKI Stock Analysis - Frequently Asked Questions How have AIKI shares performed in 2024? AIkido Pharma's stock was trading at $2.59 at the start of the year. Since then, AIKI stock has increased by 4.6% and is now trading at $2.71. View the best growth stocks for 2024 here. When did AIkido Pharma's stock split? Shares of AIkido Pharma reverse split on the morning of Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of AIkido Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), Nuwellis (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV). How do I buy shares of AIkido Pharma? Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does AIkido Pharma have any subsidiaries? The following companies are subsidiares of AIkido Pharma: Hoth Therapeutics.Read More This page (NASDAQ:AIKI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIkido Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
